AP2817A - Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same - Google Patents

Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same

Info

Publication number: AP2817A
Authority: AP; ARIPO
Prior art keywords: methods; includingpolymorphs; sulfonamides; arylamino; mek
Prior art date: 2007-07-30

Application number

AP2010005134A

Other versions

AP2010005134A0 (en

Inventor

Jean-Michel Vernier

Collin Edward Rowlings

Jean-Luc Gi-Rardet

Original Assignee

Ardea Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-07-30

Filing date

2008-07-28

Publication date

2013-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2817(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-07-30 Priority claimed from US11/830,733 external-priority patent/US8101799B2/en

2008-07-28 Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc

2010-02-28 Publication of AP2010005134A0 publication Critical patent/AP2010005134A0/en

2013-12-31 Application granted granted Critical

2013-12-31 Publication of AP2817A publication Critical patent/AP2817A/en

Links

Classifications

- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
- A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
- A01N41/04—Sulfonic acids; Derivatives thereof
- A01N41/06—Sulfonic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
- C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

AP2010005134A 2007-07-30 2008-07-28 Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same AP2817A (en)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US11/830,733 US8101799B2 (en)	2005-07-21	2007-07-30	Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P	2008-03-06	2008-03-06
US3446608P	2008-03-06	2008-03-06
US4488608P	2008-04-14	2008-04-14
PCT/US2008/071392 WO2009018233A1 (en)	2007-07-30	2008-07-28	Derivatives of n-(arylamino) sulfonamides including polymorphs as inhibitors of mek as well as compositions, methods of use and methods for preparing the same

Publications (2)

Publication Number	Publication Date
AP2010005134A0 AP2010005134A0 (en)	2010-02-28
AP2817A true AP2817A (en)	2013-12-31

Family

ID=40304796

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AP2010005134A AP2817A (en)	2007-07-30	2008-07-28	Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same

Country Status (23)

Country	Link
EP (1)	EP2184984A4 (en)
JP (3)	JP2010535232A (en)
KR (3)	KR20140098185A (en)
CN (2)	CN101808516B (en)
AP (1)	AP2817A (en)
AU (2)	AU2008282338B2 (en)
BR (1)	BRPI0815659A2 (en)
CA (1)	CA2693390C (en)
CO (1)	CO6470808A2 (en)
CR (1)	CR11244A (en)
DO (1)	DOP2010000045A (en)
EA (2)	EA020624B1 (en)
EC (1)	ECSP109910A (en)
HK (1)	HK1147396A1 (en)
HN (1)	HN2010000203A (en)
IL (1)	IL203296A (en)
MA (1)	MA31881B1 (en)
MX (1)	MX2010001244A (en)
NZ (1)	NZ582929A (en)
PH (1)	PH12015501914A1 (en)
SV (1)	SV2010003469A (en)
TN (1)	TN2010000049A1 (en)
WO (1)	WO2009018233A1 (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7723477B2 (en)	2005-10-31	2010-05-25	Oncomed Pharmaceuticals, Inc.	Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
EP2291350A4 (en) *	2008-04-14	2012-09-19	Ardea Biosciences Inc	Compositions and methods for preparing and using same
BR122021020474B1 (en) *	2008-09-09	2022-06-07	F. Hoffmann-La Roche Ag	Acyl sulfonamide polymorphs, their use, their preparation process and pharmaceutical composition that comprises them
RU2579897C2 (en)	2008-09-26	2016-04-10	Онкомед Фармасьютикалс, Инк.	Agents linking frizzled receptor and their use
UY32486A (en) *	2009-03-11	2010-10-29	Ardea Biosciences Inc	TREATMENT OF CANCER CANCER
EP2405908B1 (en) *	2009-03-11	2016-12-21	Ardea Biosciences, Inc.	Pharmaceutical combination of rdea119/bay 869766 and gemcitabine for the treatment of specific cancers
KR20120094165A (en)	2009-10-13	2012-08-23	알로스팀 테라퓨틱스 엘엘씨	Novel mek inhibitors, useful in the treatment of diseases
JP2013508318A (en) *	2009-10-21	2013-03-07	バイエル・ファルマ・アクチェンゲゼルシャフト	Substituted benzosulfonamide derivatives
TWI535445B (en)	2010-01-12	2016-06-01	安可美德藥物股份有限公司	Wnt antagonists and methods of treatment and screening
CN102020651B (en)	2010-11-02	2012-07-18	北京赛林泰医药技术有限公司	6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) *	2011-02-23	2012-08-29	苏州波锐生物医药科技有限公司	Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
BR112013027448A2 (en) *	2011-04-28	2020-09-01	Sloan-Kettering Institute For Cancer Research	combination therapy with hsp90
JP5965993B2 (en) *	2011-05-27	2016-08-10	バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒＩｎｔｅｌｌｅｃｔｕａｌＰｒｏｐｅｒｔｙＧｍｂＨ	Chiral synthesis of N- {3,4-difluoro-2-[(2-fluoro-4-iodophenyl) amino] -6-methoxyphenyl} -1- [2,3-dihydroxy-propyl] cyclopropanesulfonamides
EP2788378A4 (en) *	2011-12-09	2015-09-09	Oncomed Pharm Inc	Combination therapy for treatment of cancer
WO2013109142A1 (en)	2012-01-16	2013-07-25	Stichting Het Nederlands Kanker Instituut	Combined pdk and mapk/erk pathway inhibition in neoplasia
US20150267258A1 (en) *	2012-05-31	2015-09-24	Bayer Pharma Aktiengesellschaft	Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
NZ702548A (en)	2012-06-04	2015-11-27	Pharmacyclics Llc	Crystalline forms of a bruton’s tyrosine kinase inhibitor
FI3702351T3 (en) *	2012-10-19	2024-01-24	Array Biopharma Inc	Formulation comprising a mek inhibitor
US20150265679A1 (en)	2012-11-02	2015-09-24	The United States Of America, As Represented By Secretary, Department Of Health And Human Services	Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
WO2014121196A1 (en)	2013-02-04	2014-08-07	Oncomed Pharmaceuticals, Inc.	Methods and monitoring of treatment with a wnt pathway inhibitor
EP2848246A1 (en)	2013-09-13	2015-03-18	Bayer Pharma Aktiengesellschaft	Pharmaceutical compositions containing refametinib
WO2015041534A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	P90rsk in combination with raf/erk/mek
WO2015041533A1 (en)	2013-09-20	2015-03-26	Stichting Het Nederlands Kanker Instituut	Rock in combination with mapk-pathway
WO2015156674A2 (en)	2014-04-10	2015-10-15	Stichting Het Nederlands Kanker Instituut	Method for treating cancer
WO2015178770A1 (en)	2014-05-19	2015-11-26	Stichting Het Nederlands Kanker Instituut	Compositions for cancer treatment
EP3185900A4 (en)	2014-08-25	2018-05-02	Aimmune Therapeutics, Inc.	Egg protein formulations and methods of manufacture thereof
SG10202102078VA (en)	2015-03-03	2021-04-29	Pharmacyclics Llc	Pharmaceutical formulations of a bruton’s tyrosine kinase inhibitor
CN110799191B (en) *	2017-06-16	2023-05-26	贝塔制药有限公司	Pharmaceutical formulations of N- (2- (2- (dimethylamino) ethoxy) -4-methoxy-5- ((4- (1-methyl-1H-indol-3-yl) pyrimidin-2-yl) amino) phenyl) acrylamide and salts thereof
CN114364798A (en)	2019-03-21	2022-04-15	欧恩科斯欧公司	Combination of Dbait molecules with kinase inhibitors for the treatment of cancer
CN114761006A (en)	2019-11-08	2022-07-15	Inserm(法国国家健康医学研究院)	Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en)	2020-01-22	2021-07-29	Onxeo	Novel dbait molecule and its use

Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6545030B1 (en) *	1999-01-13	2003-04-08	Warner-Lambert Company	1-heterocycle substituted diarylamines
US6780870B2 (en) *	2000-02-11	2004-08-24	Smithkline Beecham Corporation	Pyrimidine derivatives as selective inhibitors of COX-2
US20040176418A1 (en) *	2000-06-15	2004-09-09	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5162117A (en) *	1991-11-22	1992-11-10	Schering Corporation	Controlled release flutamide composition
JP2575590B2 (en) *	1992-07-31	1997-01-29	塩野義製薬株式会社	Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
DE122007000045I2 (en) *	1992-08-25	2011-07-21	Gd Searle Llc Gd Searle Llc	Darunavir or pharmaceutically acceptable salts, hydroxyethylaminosulfonamides, useful as inhibitors or prodrugs thereof. of retroviral proteases.
CA2461227C (en) *	2001-09-24	2012-05-15	Jessie L.-S Au	Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
AU2003251942A1 (en) *	2002-07-17	2004-02-02	Titan Pharmaceuticals, Inc.	Combination of chemotherapeutic drugs for increasing antitumor activity
AR040717A1 (en) *	2002-07-30	2005-04-20	Zentaris Ag	USE OF ALKYLPHOSPHOCOLINES IN COMINATION WITH ANTITUMORAL MEDICINES FOR THE TREATMENT OF MALIGNAL AND BENIGAL ONCOSIS IN HUMAN AND ANIMAL BEINGS
BRPI0607537A2 (en) *	2005-04-12	2009-09-15	Elan Pharma Int Ltd	nanoparticulate quinazoline derivative formulations
CA2605381A1 (en) *	2005-04-22	2006-11-02	Kissei Pharmaceutical Co., Ltd.	Crystal polymorphism of 4'-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3',5'-dimethylbiphenylcarboxylic acid hydrochloride
MX2008002114A (en) *	2005-07-21	2008-04-17	Ardea Biosciences Inc	N-(arylamino)-sulfonamide inhibitors of mek.
JP2007099763A (en) *	2005-09-08	2007-04-19	Toyama Chem Co Ltd	New crystal of piperacillin sodium-1 hydrate and method for producing the same
TW200800150A (en) *	2005-12-21	2008-01-01	Organon Nv	Compounds with medicinal effects due to interaction with the glucocorticoid receptor

2008
- 2008-07-28 NZ NZ582929A patent/NZ582929A/en not_active IP Right Cessation
- 2008-07-28 CN CN2008801088296A patent/CN101808516B/en not_active Expired - Fee Related
- 2008-07-28 KR KR1020147017261A patent/KR20140098185A/en not_active Application Discontinuation
- 2008-07-28 MX MX2010001244A patent/MX2010001244A/en active IP Right Grant
- 2008-07-28 CA CA2693390A patent/CA2693390C/en not_active Expired - Fee Related
- 2008-07-28 JP JP2010520118A patent/JP2010535232A/en active Pending
- 2008-07-28 BR BRPI0815659-0A2A patent/BRPI0815659A2/en not_active Application Discontinuation
- 2008-07-28 EA EA201000268A patent/EA020624B1/en not_active IP Right Cessation
- 2008-07-28 AP AP2010005134A patent/AP2817A/en active
- 2008-07-28 KR KR1020107004742A patent/KR20100092424A/en active Search and Examination
- 2008-07-28 CN CN201310317815.8A patent/CN103479604B/en not_active Expired - Fee Related
- 2008-07-28 EP EP08796733.7A patent/EP2184984A4/en not_active Ceased
- 2008-07-28 AU AU2008282338A patent/AU2008282338B2/en not_active Ceased
- 2008-07-28 KR KR1020157020493A patent/KR20150091434A/en not_active Application Discontinuation
- 2008-07-28 EA EA201400552A patent/EA032294B1/en not_active IP Right Cessation
- 2008-07-28 WO PCT/US2008/071392 patent/WO2009018233A1/en active Application Filing
2010
- 2010-01-13 IL IL203296A patent/IL203296A/en not_active IP Right Cessation
- 2010-01-29 DO DO2010000045A patent/DOP2010000045A/en unknown
- 2010-01-29 EC EC2010009910A patent/ECSP109910A/en unknown
- 2010-01-29 TN TNP2010000049A patent/TN2010000049A1/en unknown
- 2010-01-29 HN HN2010000203A patent/HN2010000203A/en unknown
- 2010-01-29 SV SV2010003469A patent/SV2010003469A/en unknown
- 2010-01-29 CR CR11244A patent/CR11244A/en not_active Application Discontinuation
- 2010-01-29 CO CO10009526A patent/CO6470808A2/en not_active Application Discontinuation
- 2010-02-19 MA MA32636A patent/MA31881B1/en unknown
2011
- 2011-02-18 HK HK11101625.8A patent/HK1147396A1/en not_active IP Right Cessation
2014
- 2014-11-14 JP JP2014231450A patent/JP6309880B2/en not_active Expired - Fee Related
2015
- 2015-01-28 AU AU2015200390A patent/AU2015200390B2/en not_active Ceased
- 2015-08-28 PH PH12015501914A patent/PH12015501914A1/en unknown
2017
- 2017-02-03 JP JP2017018477A patent/JP2017125021A/en active Pending

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6545030B1 (en) *	1999-01-13	2003-04-08	Warner-Lambert Company	1-heterocycle substituted diarylamines
US7115632B1 (en) *	1999-05-12	2006-10-03	G. D. Searle & Co.	Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6780870B2 (en) *	2000-02-11	2004-08-24	Smithkline Beecham Corporation	Pyrimidine derivatives as selective inhibitors of COX-2
US20040176418A1 (en) *	2000-06-15	2004-09-09	Schering Corporation	Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist

Also Published As

Publication number	Publication date
SV2010003469A (en)	2010-04-30
AP2010005134A0 (en)	2010-02-28
CN101808516B (en)	2013-08-28
HN2010000203A (en)	2012-11-19
AU2008282338A1 (en)	2009-02-05
CO6470808A2 (en)	2012-06-29
PH12015501914A1 (en)	2017-07-31
KR20100092424A (en)	2010-08-20
EA201400552A1 (en)	2014-09-30
JP2015078199A (en)	2015-04-23
IL203296A (en)	2017-06-29
DOP2010000045A (en)	2010-10-31
EA020624B1 (en)	2014-12-30
MX2010001244A (en)	2010-08-31
CA2693390C (en)	2017-01-17
NZ582929A (en)	2012-03-30
AU2008282338B2 (en)	2015-02-12
ECSP109910A (en)	2010-04-30
BRPI0815659A2 (en)	2014-09-30
HK1147396A1 (en)	2011-08-12
CR11244A (en)	2010-05-20
EP2184984A1 (en)	2010-05-19
KR20150091434A (en)	2015-08-10
CN103479604A (en)	2014-01-01
CN101808516A (en)	2010-08-18
MA31881B1 (en)	2010-12-01
CA2693390A1 (en)	2009-02-05
JP2017125021A (en)	2017-07-20
TN2010000049A1 (en)	2011-09-26
CN103479604B (en)	2016-08-10
EA201000268A1 (en)	2010-08-30
JP6309880B2 (en)	2018-04-11
WO2009018233A1 (en)	2009-02-05
KR20140098185A (en)	2014-08-07
EA032294B1 (en)	2019-05-31
JP2010535232A (en)	2010-11-18
AU2015200390B2 (en)	2017-02-23
EP2184984A4 (en)	2013-07-24

Publication	Publication Date	Title
AP2817A (en)	2013-12-31	Derivatives of n-(arylamino)sulfonamides includingpolymorphs as inhibitors of mek as well as compos itions, methods of use and methods for preparing the same
AU2015200390A1 (en)	2015-02-19	Derivatives of N-(arylamino) sulfonamides including polymorphs as inhibitors of MEK as well as compositions, methods of use and methods for preparing the same
IL222698A0 (en)	2012-12-31	Benzazole derivatives, compositions, and methods of use as b- secretase inhibitors
PH12015501484A1 (en)	2017-06-05	Heteroaryl compounds and uses thereof
IL192580A0 (en)	2009-02-11	Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
IL192298A (en)	2016-02-29	Heterocyclic compounds, pharmaceutical acceptable salts thereof, pharmaceutical compositions comprising the same and uses thereof
EP2154965A4 (en)	2011-08-17	Naphthyridine, derivatives as p13 kinase inhibitors
DK2074122T5 (en)	2014-03-17	PYRIDO (2, 3-D) PYRIMIDINON COMPOUNDS AND USE THEREOF AS PI3 INHIBITORS
HK1127354A1 (en)	2009-09-25	Heteroaryl-substituted arylaminopyridine derivatives as mek inhibitors mek
ZA200807447B (en)	2009-11-25	Thieno-Pyridine derivatives as MEK inhibitors
HRP20130585T1 (en)	2013-07-31	Alkylthiazol carbamate derivatives, preparation thereof and their use as faah inhibitors
HK1099300A1 (en)	2007-08-10	Substituted n-arylsulfonylheterocyclic amines as gamma-secretase inhibitors
WO2006039250A3 (en)	2006-10-19	Chemokine-binding heterocyclic compound salts, and methods of use thereof
ZA200905671B (en)	2010-10-27	Heterocyclic compounds, compositions comprising them and methods of their use
EP1954685A4 (en)	2009-11-11	Furoxan compounds, compositions and methods of use
ZA200702596B (en)	2009-09-30	Novel bis-azaindole derivatives, preparation and pharmaceutical use thereof as kinase inhibitors
IL179076A0 (en)	2007-03-08	Azasugasr derivatives, heparanase inhibitors, method for preparing same, compositions containing same, use thereof
IL209945A0 (en)	2011-02-28	Novel derivatives of pyrroloindole inhibitors of hsp90; compositions containing same, and use thereof
EP2320738A4 (en)	2011-08-24	Substituted aminothiazole derivatives, pharmaceutical compositions, and methods of use
IL190230A0 (en)	2008-11-03	Derivatives of 2-aminthiazoles and 2-aminooxazoles, processes for their preparation and their use as pharmaceuticals
ZA200808598B (en)	2009-12-30	Pyrrolopyrimidine derivatives used as HSP90 inhibitors
TH0901000961A (en)	2016-04-07	N-(arylamino)sulfonamide derivatives including polymorphs as MEK inhibitors and constituents, methods of use. and methods for preparing the same substances
EP2213650A4 (en)	2014-04-02	Substituted diphenylamines as inhibitors of reverse transcriptase, process of preparing them and use thereof
IL191861A0 (en)	2009-08-03	Improved jasmonate derivatives, pharmaceutical compositions and methods of use thereof
IL210842A (en)	2016-05-31	Single, solid composition comprising a protein, a protease inhibitor and a salt of nac or nad and uses thereof for oral administration of the protein